Here we achieved the discovery and validation of the RASSF10 biomarker across different kidney tumor types, which in the next steps of biomarker development will have to be followed by assay development and analytical validation, clinical utility validation, and ultimately clinical implementation [2]. The gene discussed is RASSF10; the disease is kidney neoplasm.